Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections

References

• CDC. Antibiotic resistance threats in the United States, 2019. Atlanta (GA): U.S. Department of Health and Human Services, CDC; 2019.
   Google Scholar
• Makary M, Das I, Hashim F, et al. The next pandemic is already here – tools for stopping it are readily available, if only we agree to use them. 2021 Jan 20. Available from: https://www.medpagetoday.com/opinion/marty-makary/90795
   Google Scholar
• Strathdee SA, Davies SC, Marcelin JR. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet. 2020;396(10257):1050–1053.
   PubMed Web of Science ®Google Scholar
• Interagency Coordination Group on Antimicrobial Resistance. No time to wait: securing the future from drug-resistant infections. 2019 April.
   Google Scholar
• Pharmaceutical Research and Manufacturers of America. 2021 Report on Antimicrobial Resistance. Medicines in Development. 2021.
   Google Scholar
• Fetroja [package insert]. Florham Park, NJ; 2019.
   Google Scholar
• Page MGP. The role of iron and siderophores in infection, and the development of siderophore antibiotics. CID. 2019;69(S7):S529–37.
   PubMedGoogle Scholar
• Zhanel GG, Golden AR, Zelenltsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs. 2019;79(3):271–289.
   PubMed Web of Science ®Google Scholar
• Nairz M, Haschka D, Demetz E, et al. Iron at the interface of immunity and infection. Front Pharmacol. 2014;5:152.
   PubMed Web of Science ®Google Scholar
• Aoki T, Yoshizawa H, Yamawaki K, et al. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem. 2018;155:847–868.
   PubMed Web of Science ®Google Scholar
• Negash KH, Norris JKS, Hodgkinson JT. Siderophore-antibiotic conjugate design: new drugs for bad bugs? Molecules. 2019;24(18):3314.
   Google Scholar
• Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev. 2007;71(3):413–451.
   PubMed Web of Science ®Google Scholar
• El-Lababidi RM, Rizk JG. Cefiderocol: a siderophore cephalosporin. Ann Pharmacother. 2020;54(12):1215–1231.
   PubMedGoogle Scholar
• Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-1: activity of cefiderocol (S-649266), a siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. Antimicrob Agents Chemother. 2019;63(1):e01801–18.
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Sadouki Z, Vickers A, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against multidrug-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2020;64(12):e01582–20.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother. 2017;61(9):e00093–17.
   PubMed Web of Science ®Google Scholar
• Wu JY, Srinivas Pogue JM, Pogue JM. Cefiderocol: a novel agent for the management of multidrug-resistant Gram-negative organisms. Infect Dis Ther. 2020;9(1):17–40.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Tsuji M, Tamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62(2):e01968–17.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Hackel MA, Tsuji M, et al., In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019;53(4): 456–466.
   PubMed Web of Science ®Google Scholar
• Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–1322.
   PubMed Web of Science ®Google Scholar
• Greenberg EP, Banin E. Control of biofilm infections by signal manipulation. Berlin (Heidelberg): Springer; 2007. p. 141–156.
   Google Scholar
• Pybus CA, Felder-Scott C, Obuekwe V, et al. Cefiderocol retains antibiofilm activity in multidrug-resistant Gram-negative pathogens. Antimicrob Agents Chemother. 2021;65(2):e01194–20.
   PubMedGoogle Scholar
• Ito A, Nishikawa T, Ishii R, et al. Mechanism of cefiderocol high MIC mutants obtained in non-clinical FoR studies. San Francisco (CA); 2018. ID Week 2018.
   Google Scholar
• Yamano Y, Takemura M, Kazmierczak K, et al. Molecular profile of β-lactamase genes and siderophore-dependent iron transporter genes of cefiderocol high MIC isolates from SIDERO-WT studies [abstract]. Open Forum Infect Dis. 2020;7(Suppl 1):S728–9.
   Google Scholar
• Yamano Y, Nakamura R, Takemura M, et al. Potential mechanisms of cefiderocol MIC increase in Enterobacterales in in vitro resistance acquisition studies [abstract]. Open Forum Infect Dis. 2020;7(Suppl 1):S730.
   Google Scholar
• Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemases- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents. 2019;53(2):177–184.
   PubMed Web of Science ®Google Scholar
• Poirel L, Sadek M, Nordmann P, et al. Contribution of PER-type and NDM-type β-lactamases to cefiderocol resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2021;65(10):e00877–21.
   Google Scholar
• Tiseo G, Falcone M, Leonildi A, et al. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3. Open Forum Infect Dis. 2021;8(6):ofab141.
   PubMedGoogle Scholar
• Streling AP, Al Obaidi MM, Lainhart MD, et al. Evaluation of cefiderocol non-susceptibility in Pseudomonas aeruginosa in a patient without previous exposure to the antibiotic. Clin Infect Dis. 2021;73(11):e4472–4.
   PubMedGoogle Scholar
• Shields RK, Iovleva A, Kline EG, et al. Clinical evolution of ampC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime. Clin Infect Dis. 2020;71(10):2713–2716.
   PubMedGoogle Scholar
• Kawai A, McElheny CL, Iovleva EG, et al. Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion. Antimicrob Agents Chemother. 2020;64(7):e00198–20.
   PubMedGoogle Scholar
• Klein S, Boutin S, Kocer K, et al. Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cira. Clin Infect Dis. 2021;72(5):e158–e161. online ahead of print.
   PubMedGoogle Scholar
• Saisho Y, Katsube T, White S, et al. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62(3):e02163–17.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Ito-Horlyama T, Takemura M, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019;63(9):e02031–18.
   PubMedGoogle Scholar
• Katsube T, Echols R, Wajima T. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(S7):S552–8.
   PubMedGoogle Scholar
• Miyazaki S, Katsube T, Shen H, et al. Metabolism, excretion, and pharmacokinetics of [14C]-Cefiderocol (S-649266), a siderophore cephalosporin, in healthy subjects following intravenous administration. J Clin Pharmacol. 2019;59(7):958–967.
   PubMed Web of Science ®Google Scholar
• Kawaguchi N, Katsube T, Echols R, et al. Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis. Antimicrob Agents Chemother. 2018;62(2):e01391–17.
   PubMed Web of Science ®Google Scholar
• Katsube T, Wajima T, Ishibashi T, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother. 2017;61(1):e01381–16.
   PubMedGoogle Scholar
• Katsube T, Saisho Y, Shimada J, et al. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J Antimicrob Chemother. 2019;74(7):1971–1974.
   PubMed Web of Science ®Google Scholar
• Katsube T, Nicolau DP, Rodvold KA, et al. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. Antimicrob Chemother. 2021;76(11): 2902–2905.
   Google Scholar
• Boselli E, Breilh D, Rimmele T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30(5):989–991.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003;31(8):2102–2106.
   PubMed Web of Science ®Google Scholar
• Shionogi. Safety, tolerability, and pharmacokinetics of cefiderocol in hospitalized pediatric patients. NLM identifier: 04215991 ( cited 15 Sept 2021). Available from: https://clinicaltrials.gov/ct2/show/record/NCT04215991
   Google Scholar
• Shionogi. Safety, tolerability, and pharmacokinetics of single and multiple doses of cefiderocol in hospitalized pediatric patients. NLM identifier: NCT04335539( cited 2021 Sept 15). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04335539
   Google Scholar
• Katsube T, Echols R, Ferreira JCA, et al. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol. 2017;57(5):584–591.
   PubMed Web of Science ®Google Scholar
• Kobic E, Gill CM, Mochon AB, et al. Cefiderocol pharmacokinetics in a patient receiving continuous venovenous hemodiafiltration. Open Forum Infect Dis. 2021;8(7):ofab252.
   PubMedGoogle Scholar
• Wenzler E, Butler D, Tan X, et al. Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy. Clin Pharmacokinet. 2021;61(4):539–552. online ahead of print.
   PubMedGoogle Scholar
• Wunderink RG, Matsunaga Y, Ariyasu M, et al., Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomized, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213–225.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al., Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomized, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240.
   PubMed Web of Science ®Google Scholar
• Katsube T, Kawaguchi N, Matsunaga Y, et al. Pharmacokinetic/pharmacodynamic analyses of cefiderocol in critically ill patients [abstract]. Open Forum Infect Dis. 2020;7(Suppl 1):S669–70.
   Google Scholar
• Gatti M, Bartoletti M, Cojutti PG, et al. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. J Glob Antimicrob Resist. 2021;27:294–298.
   PubMed Web of Science ®Google Scholar
• Katsube T, Miyazaki S, Narukawa Y, et al. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Eur J Clin Pharmacol. 2018;74(7):931–938.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Singley CM, Hoover J. Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother. 2017;61(9):e00700–17.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Tsuji M, Yamano Y, et al. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn Microbiol Infect Dis. 2019;94(4):321–325.
   PubMedGoogle Scholar
• Huband MD, Ito A, Tsuij M, et al. Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using CLSI M23-A4 multi-laboratory study design. Diagn Microbiol Infect Dis. 2017;88(2):198–200.
   PubMedGoogle Scholar
• Ghazi IM, Monogue ML, Tsuji M, et al. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin in Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents. 2018;51(2):206–212.
   PubMed Web of Science ®Google Scholar
• Monogue ML, Tsuji M, Yamano Y, et al. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61(11):e01022–17.
   PubMed Web of Science ®Google Scholar
• Meschiari M, Volpi S, Faltoni M, et al. Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections. J Antimicrob Resist. 2021;3(4):dlab188.
   PubMedGoogle Scholar
• Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72(11):2021–2024.
   PubMed Web of Science ®Google Scholar
• Bavaro DF, Belati A, Diella L, et al. Cefiderocol-based combination therapy for “difficult-to-treat” Gram-negative severe infections: real-life case series and future perspectives. Antibiotics. 2021;10(6):652.
   Google Scholar
• Portsmouth S, van Veenhuyzen D, Echols R, et al., Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomized, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–1328.
   PubMed Web of Science ®Google Scholar
• Fetcroja [package insert]. Amsterdam, The Netherlands: 2020.
   Google Scholar
• Paterson DS. RCT cefiderocol vs BAT for treatment of Gram-negative BSI (GAMECHANGER). NLM identifier: NCT03869437 ( cited 2021 Sept 15). Available from: https://clinicaltrials.gov/ct2/show/NCT03869437
   Google Scholar
• Roberts JA, Paratz J, Paratz E, et al., Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007;30(1):11–18.
   PubMed Web of Science ®Google Scholar
• Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021;3(4):dlab174.
   PubMedGoogle Scholar